Avalo Therapeutics received multiple rating changes and analyst coverage from firms including Cantor Fitzgerald, Bank of America, and Weiss Ratings.
1 report, 1 independent
Updated Sep 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Avalo Therapeutics received multiple rating changes and analyst coverage from firms including Cantor Fitzgerald, Bank of America, and Weiss Ratings.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
Related events
- Cantor Fitzgerald started coverage and upgraded its rating from strong sell to sell for Critical Metals Corp. on September 12, 2026.
- Various financial firms, including JPMorgan Chase & Co. and Barclays, made rating upgrades, rating reaffirms, and acquired new stakes in a company during the second quarter of 2026.
- Rating firms Cantor Fitzgerald and Citigroup issued updates regarding Quanta Services, including boosting the target price and giving a buy rating.
- MarketBeat reported on analyst coverage for IONQ, noting that Needham reiterated its buy rating, while Cantor Fitzgerald set a $70.00 price target and reiterated its overweight rating.
- Modiv Industrial stock saw an analyst downgrade to 'Hold' and increased stake by a hedge fund.